Entasis Therap patents expiration
1. Xacduro (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9309245 | ENTASIS THERAP | Beta-lactamase inhibitor compounds |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9623014 | ENTASIS THERAP | β-lactamase inhibitor compounds |
Apr, 2033
(8 years from now) | |
| US10376499 | ENTASIS THERAP | Combination therapy for treatment of resistant bacterial infections |
Nov, 2035
(11 years from now) | |
| US9968593 | ENTASIS THERAP | Combination therapy for treatment of resistant bacterial infections |
Nov, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2033 |
Drugs and Companies using DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM ingredient
NCE-1 date: 23 May, 2032
Market Authorisation Date: 23 May, 2023
Treatment: Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp)
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
XACDURO (COPACKAGED) family patents
